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ABBREVIATIONS
ASD Autism spectrum disorder
RCT Randomized controlled trial
SOL Sleep onset latency
TST Total sleep time
AIM To evaluate the effectiveness of pharmacological interventions for managing non-
respiratory sleep disturbances in children with neurodisabilities.
METHOD We performed a systematic review and meta-analyses of randomized controlled
trials (RCTs). We searched 16 databases, grey literature, and reference lists of included
papers up to February 2017. Data were extracted and assessed for quality by two researchers
(B.B., C.M., G.S., A.S., A.P.).
RESULTS Thirteen trials were included, all evaluating oral melatonin. All except one were at
high or unclear risk of bias. There was a statistically significant increase in diary-reported
total sleep time for melatonin compared with placebo (pooled mean difference 29.6min, 95%
confidence interval [CI] 6.9–52.4, p=0.01). Statistical heterogeneity was high (97%). For the
single RCT with low risk of bias, the unadjusted mean difference in total sleep time was
13.2 minutes (95% CI 13.3 to 39.7) favouring melatonin, while the mean difference adjusted
for baseline total sleep time was statistically significant (22.4min, 95% CI 0.5–44.3, p=0.04).
Adverse event profile suggested that melatonin was well-tolerated.
INTERPRETATION There is a paucity of evidence on managing sleep disturbances in children
with neurodisabilities, and it is mostly of limited scope and poor quality. There is evidence of
the benefit and safety of melatonin compared with placebo, although the extent of this
benefit is unclear.
Sleep is fundamental to healthy physical and mental func-
tioning and well-being. However, sleep disturbances in
children are common. For children with neurodisabilities,
sleep disturbances are more common and more severe
compared with typically developing children.1 For chil-
dren, sleep disturbance can affect educational progress and
daytime behaviour.2 It can also have a detrimental impact
on the physical and emotional well-being of other family
members; for example, children’s sleep disturbance is asso-
ciated with heightened levels of parental stress and irri-
tability.3,4 These outcomes may create additional support
needs and, consequently, increase demands on statutory
services, such as respite care.5 More widely, the economic
consequences of poor sleep are being recognized.6,7 Sleep
management is a research priority in children with
neurodisabilities.8 Parents also consistently highlight their
need for support with their child’s sleep problems.9–11
The clinical and research literature uses numerous alter-
native phrases to describe sleep disorder in terms of its
impact on an individual’s sleep, such as ‘sleep disturbance’,
‘sleep problems’, and ‘sleep difficulties’.12 Such terms have
all been used to describe difficulties with falling asleep (i.e.
sleep initiation) and staying asleep, as opposed to night
wakings or very early waking (i.e. sleep maintenance).
Regardless of the term used, difficulties with sleep initia-
tion and sleep maintenance result in disturbed sleep and/or
sleep deprivation, not only for the individual concerned
but often also for other members of the household.
Interventions to address sleep disturbance among children
with neurodisabilities include both pharmacological and
non-pharmacological approaches. Pharmacological interven-
tions act on the physiological processes of sleep, the timing
of the sleep–wake cycle, or both. The most frequently used
pharmacological treatment is melatonin, the hormone
involved in controlling the sleep–wake cycle.13–15 Many
paediatricians and general practitioners prescribe melatonin
for children, despite it not currently being licensed for chil-
dren. In 2005, an anonymous survey of 148 paediatricians in
the UK suggested that 98% were currently prescribing or
had prescribed melatonin in the previous year.16 Although
not currently licensed, melatonin is available over the Inter-
net and over the counter in some countries such as the
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USA, where a survey of paediatricians reported that 25%
had recommended melatonin for paediatric insomnia in
children with and without neurodisabilities.17 In the UK
there are currently more than 6000 children being treated
with melatonin.18 Other pharmacological interventions
include medicines that have a sedative effect, such as cloni-
dine and antihistamines. All are prescribed ‘off-label’.
Current guidance on the management of sleep disturbance
in children advocates that, once clinical or respiratory rea-
sons for sleep disturbance are excluded, parent-directed
interventions that seek to change parents’ responses to sleep-
related problems should be the ‘first port of call’ for any
child,13,19–21 with pharmacological intervention (typically
melatonin) suggested in cases where such approaches prove
ineffective and/or to be used alongside parent-directed
approaches.12,22 However, current practice in prescribing
medicines such as melatonin has been described as haphaz-
ard.18 For melatonin, guidance states that it should be con-
sidered for improving sleep onset latency (SOL) in children
with neurodisabilities of any form whose sleep problems
have not resolved after implementation of behavioural inter-
ventions.20 The guidance also states that melatonin should
be used in conjunction with behavioural interventions.23 For
children with autism spectrum disorder (ASD) and any type
of sleep disorder, current guidance stipulates that parent-
directed behavioural interventions should be implemented
first before pharmacological interventions; and that where
pharmacological interventions are used, this should be in
conjunction with behavioural interventions.23,24
Previous systematic reviews of pharmacological interven-
tions for managing sleep disturbance have focused on indi-
vidual neurodisabilities such as ASD or attention-deficit/
hyperactivity disorder.25–30 Therefore, a systematic review
assessing the effect of pharmacological interventions on
sleep disturbance across the neurodisability spectrum is
needed, to inform both clinical practice and research.
This systematic review was commissioned by the Health
Technology Assessment programme of the UK National
Institute for Health Research (NIHR). The NIHR required
the review to focus on the management of ‘non-respiratory
sleep disturbance’ in children with neurodisabilities and that
sleep disturbance (affecting the child and/or parent) was a
feature of the presenting problem. The commissioning brief
was broad and included effectiveness and safety of pharma-
cological and non-pharmacological interventions to manage
sleep disturbances in children with neurodisabilities. In this
paper we focus on the effectiveness and safety of pharmaco-
logical interventions. Findings with respect to non-pharma-
cological interventions are reported elsewhere.31,32
We aimed to evaluate and summarize the existing evidence
about the effectiveness of pharmacological interventions on
sleep disturbances for children with neurodisabilities. Where
possible, we planned to undertake subgroup analyses to
examine whether intervention effectiveness differed between
different types of neurodisability, and whether it was admin-
istered in parallel or sequentially to another sleep manage-
ment intervention.
METHOD
This systematic review was undertaken in accordance with
the Centre for Reviews and Dissemination’s ‘Guidance for
Undertaking Reviews in Health Care’33 and is reported in
line with the Preferred Reporting Items for Systematic
Reviews and Meta-Analyses (PRISMA) guidelines.34 Data
synthesis was undertaken in accordance with the Cochrane
handbook.35 The review protocol was prospectively registered
with PROSPERO (registration number CRD42016034067).
Inclusion and exclusion criteria
Studies were assessed for eligibility on the basis of the cri-
teria outlined in Table SI (online supporting information).
Concerns have been expressed by others that a crossover
design may be inappropriate because of uncertainty about
the duration of the effect of interventions on sleep patterns
and circadian rhythm and therefore the most appropriate
duration for the washout period.18 We agree with these
concerns. However, given that the aim was to undertake a
broad review and there were few randomised controlled
trials (RCTs) likely to be available, we included crossover
studies. In this paper we focus on child-related outcomes.
Information sources
Databases searched included Applied Social Science
Abstracts & Indexes (ASSIA); the Cochrane Central Regis-
ter of Controlled Trials (CENTRAL); Cochrane Database
of Systematic Reviews (CDSR); Conference Proceedings
Citation Index; Cumulative Index to Nursing & Allied
Health (CINAHL); Database of Abstracts of Reviews of
Effects (DARE); Embase; Health Management Information
Consortium (HMIC); MEDLINE; MEDLINE In-Process;
PsycINFO; Science Citation Index; Social Care Online;
and Social Policy & Practice. Searches were undertaken in
February and March 2016, and updated in February 2017.
The database ClinicalTrials.gov, the World Health
Organization’s International Clinical Trials Registry Plat-
form (ICTRP), and the UK Clinical Trials Gateway were
also searched for ongoing and completed trials. We
reviewed the reference lists of relevant systematic reviews
and included studies. Searches were not limited by date,
language, or study design. The search strategy was broad
and aimed to identify both pharmacological and non-phar-
macological interventions. Appendix S1 (online supporting
information) outlines the search strategy used for Medline,
which was adapted for use in other databases.
Selection process
Search results were imported into EndNote (version
17.0.2.7390, Clarivate Analytics [formerly Thomson
What this paper adds
• Melatonin for the management of non-respiratory sleep disturbances in children
with neurodisabilities was well tolerated with minimal adverse effects.
• The extent of benefit and which children might benefit most from melatonin
use is uncertain.
• Benefit may be greatest in those with autism spectrum disorder; however,
this finding should be interpreted with caution.
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Reuters], Philadelphia, PA, USA) and deduplicated. Record
titles were initially screened for relevance, independently by
two researchers (BB and GS) for 10% of titles, with review
of decisions halfway through. The agreement rate was mod-
erate (K=0.49), and we discussed and resolved reasons for
all disagreements. By the end of this process, only unani-
mous decisions were made. The remainder were therefore
screened by a single researcher. Selection of potentially rel-
evant abstracts and assessment of full-text articles were
done independently, by two researchers. A third researcher
was consulted where there was disagreement.
Data extraction
Data extraction forms for study details were developed and
piloted in Microsoft Excel 2010 and Microsoft Word
2010. All data were extracted by a researcher and checked
by a second. Data extracted included study design (setting,
aims, inclusion criteria, recruitment method, etc.), inter-
vention and comparator details, evaluation methods (out-
comes measured, length of follow-up, etc.) and results at
follow-up. Follow-up was defined as the closest assessment
time point after the completion of the intervention.
Assessment of risk of bias
The Cochrane Risk of Bias Tool36 was used to assess this
aspect of study quality. Risk of bias was independently
assessed by two researchers, with disagreements resolved
through discussion or with recourse to a third researcher.
For crossover trials we also assessed whether an appropri-
ate analysis using paired data was conducted and whether
there was a treatment by period interaction.37
A summary risk of bias score was calculated as follows:
studies with one or more of the domains on the risk of bias
tool classified as ‘no’ (i.e. high risk) were scored at high risk
of bias. Studies with one or more domains on the risk of
bias tool scored as ‘unclear’ were scored at unclear risk of
bias. Studies with all domains on the risk of bias tool classi-
fied as ‘yes’ (i.e. low risk) were scored at low risk of bias.36
Data synthesis
A narrative synthesis and meta-analyses were used. First, a
narrative and tabular summary of key study characteristics
were undertaken to map the population characteristics, in
particular the type of neurodisability and the type of sleep
disturbance being targeted (e.g. sleep initiation).
Meta-analyses included parallel RCTs, and crossover tri-
als with a washout period of any duration where data from
both treatment periods were used. Crossover trials without
a washout period were reported separately. The mean dif-
ference and its standard error between intervention and
comparison groups at the end point were either taken as
reported in the article or calculated using standard formu-
lae, following recommendations provided in the Cochrane
handbook.35 Data were pooled using a random effects
model (for continuous outcomes) using the generic inverse
variance method in RevMan.38 For parallel-group RCTs,
unadjusted mean differences were primarily used in the
meta-analyses, but sensitivity analyses were conducted
including mean differences adjusted for baseline using either
estimates reported in the paper from regression techniques
or calculated differences in change from baseline.
Sleep efficiency was calculated as a percentage, to repre-
sent time spent sleeping as a proportion of total time in bed.
Number of night wakings was a count variable. Such vari-
ables may not be normally distributed so analysis based on
untransformed means may not be appropriate. Individual
patient data were not available and only untransformed sum-
maries (e.g. means and standard deviations [SDs]) for these
outcomes were given in the original papers. Therefore, fol-
lowing the advice for the meta-analysis of skewed data in the
Cochrane handbook,35 a (crude) assessment of skew was
made using the untransformed means and SDs. This was
possible as we knew the maximum and/or minimum possible
values for these outcomes. For sleep efficiency, if the highest
possible value (here, 100) minus the observed mean, divided
by the SD, was less than 2, then skew was indicated.39 For
night wakings, the lowest possible value (0) was subtracted
from the mean value before dividing by the SD. Sensitivity
analyses were performed to remove trials where significant
skew was indicated, and caution in the interpretation of
results was included where appropriate.
Heterogeneity was explored using the I2 statistic.40 Two
sources of potential clinical and methodological hetero-
geneity were identified for the included studies, and, where
appropriate, subgroup analyses were conducted, stratifying
the trials as follows: by type of neurological disorder
(whether the population studied primarily had a diagnoses
of ASD or not); and by receipt of previous intervention
(whether participants were offered an additional interven-
tion [parent-directed or otherwise] immediately before the
start of the study or not).
Data preparation was undertaken in Stata 13 (StataCorp,
College Station, TX, USA), and data analyses were per-
formed in RevMan 5 (Review Manager, The Nordic
Cochrane Centre, The Cochrane Collaboration, Copen-
hagen, Denmark, 2014). Where data could not be pooled,
summaries of the findings for each trial and outcome are
presented with a (estimated unadjusted) mean difference
and 95% confidence interval (CI) between the pharmaco-
logical intervention and comparison group at follow-up.
The risk of publication bias was not formally assessed.
Adverse event data were summarized narratively.
RESULTS
Search results
We identified 15 745 records after deduplication, assessed
387 full-text records, and included 13 RCTs, all of which
investigated the use of oral melatonin as the pharmacologi-
cal intervention. We did not identify any eligible trials
evaluating another pharmacological intervention, so the
remainder of the results therefore only concern trials of
melatonin. The study selection process and reasons for
exclusion are detailed in Figure S1 (online supporting
information). A list of excluded studies is available at
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https://www.journalslibrary.nihr.ac.uk/programmes/hta/
1421202/#/.
Study characteristics
Study characteristics are outlined in Table SII (online sup-
porting information). The studies were undertaken in the
following countries: Canada (four studies);41–44 Italy (one
study);45 the Netherlands (one study);46 UK (four stud-
ies);18,47–49 and the USA (three studies).50–52 Ten RCTs
compared melatonin with placebo; one compared melatonin,
a parent-directed sleep-focused cognitive behavioural ther-
apy, and a combination of the two with placebo; and two
compared two regimens of melatonin (5mg vs 10mg; and
fast-release verses sustained release). Ten were crossover tri-
als and three were parallel-group RCTs. Sample sizes ran-
ged from six to 160 participants.
Owing to the different terminology used to describe
sleep disturbances in the included studies, we classified
assessment of sleep outcomes under the following head-
ings: global sleep outcomes and composite scores; sleep
initiation (e.g. sleep latency, sleep association, settling,
bedtime resistance); sleep maintenance (e.g. night waking,
waking time, parasomnia, cosleeping to manage night wak-
ing, sleep fragmentation), and sleep scheduling (e.g. day-
time sleepiness).
Risk of bias within studies
Only one RCT was assessed as having a low risk of bias
across all domains,18 with the remaining RCTs having high
or unclear risk of bias (Table SII). We could not locate a
prospective registration of 11 studies in order to check
planned outcome measures, meaning they were at unclear
risk of selective reporting.41–43,45–48,50–52 All of the studies
were described by their authors as being randomized; how-
ever, seven studies failed to provide details of the method of
random allocation;41–43,46,48,50,52 and four studies provided
little or no detail about allocation concealment.41,45,50,52
Similarly, it was unclear in three studies whether and how
blinding was undertaken.41,43,47 Missing data were not ade-
quately addressed in the analysis for three studies.45,47,50
Melatonin versus placebo
Eleven trials (n=589 randomized participants) compared mela-
tonin against placebo: eight crossover trials;41–43,47,48,50–52 two
two-armed, parallel-group trials;18,46 and one four-armed par-
allel-group trial of oral melatonin, parent-directed sleep man-
agement intervention (on the basis of cognitive behavioural
principles), oral melatonin plus parent-directed intervention
and oral placebo.45
The age of participants ranged from 1 to 18 years old
and the mean age ranged from 5 years 6 months to
10 years 4 months. Four RCTs included children with a
mix of neurodisabilities,18,41,42,50 three RCTs only included
children with ASD,45,47,48 two trials included only children
with attention-deficit/hyperactivity disorder,43,46 one trial
included children with ASD and/or fragile X syndrome,52
and one RCT included children with epilepsy.51
Two trials used ‘controlled-release’ melatonin.42,45 One
trial each described the formulation as ‘immediate-
release’,18 ‘fast-release’,46 ‘standard-release’,48 ‘short-act-
ing’,43 and ‘sustained-release’ melatonin.51 Four trials did
not report formulation.41,47,50,52 Six trials varied dosage on
the basis of the child’s age and/or weight and response,
from 0.5mg to 10mg (Table SII).18,41,46,48 Fixed dosages
ranged from 3mg to 9mg.42,44,45,47,50–52 Matched placebos
were used except for one RCT where details of the placebo
were not specified.43 The duration of treatment was
between 10 days and 12 weeks. Two crossover RCTs had
no washout period.41,52 The remaining crossover RCTs
had a washout period of between 3 days and
1 month.42,43,47,48,50,51
Seven RCTs required that an immediately preceding par-
ent-directed sleep management intervention had been inef-
fective for children to be included in the trial.18,41–43,47,48,50
Two of these trials did not report the specific nature of the
intervention.41,50 In two trials, guidance on sleep was pro-
vided in the form of an advice booklet;18,47 and in three tri-
als, advice about sleep hygiene and behaviour management
was provided face-to-face.43,48,52
The most commonly measured sleep-related outcomes,
measured by actigraphy and/or parent-reported diaries/
questionnaires, were total sleep time (TST) (n=11 trials);
SOL (n=10); number of night wakings (n=6); and sleep
efficiency (n=5). Other sleep outcomes assessed in fewer
than two studies included bedtime,45,51 wake up time,46,51
the Child Sleep Habits Questionnaire,45 difficulty falling
asleep,46 sleep onset,48 longest sleep episode,42 the Sleep
Behaviour Questionnaire,51 percentage of sleep stages,51
wake after sleep onset,45,51 nights without awakening,41
naptime,45 moving time,46 and arousal.51
In terms of outcomes that were not child sleep-focused,
the following additional child outcomes were reported, but
only by single RCTs: child-related quality of life (Paedi-
atric Quality of Life Questionnaire); Quality of Life in
Childhood Epilepsy; Netherlands Organisation for Applied
Scientific Research Academic Medical Centre Children’s
Quality Of Life Questionnaire (TNO-AZL);18,46,51 child
daytime behaviour and cognition (Aberrant Behaviour
Checklist; Behaviour Assessment System for Children;
Conner’s Attention Deficit Scale-Parent; Child Behaviour
Checklist; teacher’s report form; sustained attention dots—
task completion time and task inaccuracy; Erikson’s
task);18,43,46,51 adherence to treatment (parent-report; med-
ication counts);45,46 and core problems.46 One further
study assessed daytime sleepiness in caregivers.18
All RCTs had follow-up immediately after the comple-
tion of the intervention, which ranged from 10 days to 12
weeks after randomization.
Global measures and composite scores
TST
All 11 RCTs (n=589 randomized participants) measured
TST. Four measured TST using parent-reported sleep
diaries only;41,47,48,50 three solely reported actigraphy-
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measured TST data;45,46,52 and four reported TST derived
from both parent-completed sleep diaries and actigraphy
data18,42,43,51 (one of which additionally used polysomno-
graphy, which was measured in a sleep laboratory setting).51
Parent-reported TST using sleep diaries
Data from seven RCTs using sleep diary-reported TST
were pooled in a meta-analysis: six crossover trials with a
washout period (n=122 analysed participants)42,43,47,48,50,51
and one parallel-group trial (n=110).18 Note that in the
forest plot (Fig. 1) the sample sizes count participants in
crossover trials twice (as being in the melatonin and pla-
cebo groups), so the total figures reported in the text and
in the figures may not match. There was a statistically sig-
nificant increase in sleep diary-reported TST with mela-
tonin compared with placebo (pooled mean difference
29.6min, 95% CI 6.9–52.4, p=0.01).
Statistical heterogeneity was high (I2=97%) and this
treatment effect is unlikely to be generalizable; however,
the effect estimates were all in the direction of benefit with
melatonin. Heterogeneity was reduced when studies were
stratified on the basis of whether the study population had
ASD exclusively or not (Fig. 1; test for subgroup differ-
ences: p<0.001; I2=99%): there was a pooled mean differ-
ence of 64.7 minutes (95% CI 58.8–70.7, I2=0%) for the
studies of ASD (n=24) and a smaller pooled mean difference
of 15.9 minutes (95% CI 9.2–22.6, I2=31%) for the studies
of mixed or other populations (n=208). There was a single
study (n=9)51 where participants had no previous parent-
directed sleep management intervention, limiting the use-
fulness of this subgroup analysis; the overall results did not
substantially change with removal of this study (Fig. S2,
online supporting information; pooled mean difference
33.0min, 95% CI 8.6–57.4, I2=95%). When the single trial
with a low risk of bias was considered alone, the unadjusted
mean difference in sleep time at follow-up was
13.2 minutes (95% CI 13.3 to 39.7) favouring melatonin.
This was the difference used in the meta-analysis. The
paper, however, additionally reported a mean difference
adjusted for baseline TST of 22.43 minutes favouring
melatonin (95% CI 0.52–44.34, p=0.045).18 When the
adjusted mean difference was used in place of the unad-
justed mean difference in the meta-analysis, the pooled
mean difference increased to 30.8 minutes (95% CI 8.3–
53.2, p=0.01). Either way, while both pooled mean differ-
ences between the treatment groups were statistically signif-
icant, neither 95% CI contained the minimum clinically
important difference of 60 minutes, which was specified at
the start of that trial.18
One RCT of six ‘n-of-1’ trials also reported sleep diary
TST but, owing to the design, could not be included in
the meta-analysis.41 We calculated the mean difference
between melatonin and placebo for parent-reported TST
to be 13.9 minutes in favour of the melatonin group (95%
CI 6.8 to 34.6, p=0.14).
Actigraphy-measured TST
Five trials (n=265 analysed participants) were pooled for
actigraphy-measured TST, comprising two crossover trials
with a washout period (n=60)42,51 and three parallel-group
trials (n=205).18,45,46 One further RCT reported that there
was no significant difference between melatonin and pla-
cebo; however, it did not provide data, so it was not
included in the meta-analysis.43
There was a statistically significant increase in actigra-
phy-measured TST with melatonin compared with placebo
(Fig. 2; pooled mean difference 31.9min, 95% CI 14.8–
49.1, p<0.001). Heterogeneity was high (I2=76%) and this
treatment effect is unlikely to be generalizable, although
the effect estimates were all in the direction of benefit with
melatonin. There was no statistically significant difference
in effect between the studies where participants received or
Study and subgroup Mean difference SE Melatonin total
Placebo 
total Weight (%) Mean difference (95% CI)
ASD
Garstang et al.47 65.4 3.1 7 7 15.5 65.40 (59.32, 71.48)
Wright et al.48 52.3 13.4 17 17 13.0 52.30 (26.04, 78.56)
64.73 (58.81, 70.65)28.52424Subtotal
Test for overall effect: Z=21.43 (p<0.001)
Not ASD
Appleton et al.18 13.2 13.5 51 59 12.9 13.20 (–13.26, 39.66)
Dodge et al.50 18 13.2 20 20 13.0 18.00 (–7.87, 43.87)
Jain et al.51 11.3 3 9 9 15.5 11.30 (5.42, 17.18)
Wasdell et al.42 31.2 7.8 50 50 14.7 31.20 (15.91, 46.49)
Weiss et al.43 15 4.8 19 19 15.3 15.00 (5.59, 24.41)
15.87 (9.15, 22.59)71.5157149Subtotal
Heterogeneity: τ²=17.61; χ²=5.80, df=4 (p=0.210); I ²=31% 
Test for overall effect: Z=4.63 (p<0.001)
29.63 (6.91, 52.35)100.0181173Total
Heterogeneity: τ²=855.84; ²=181.18, df=6 (p<0.001); I ²=97% 
Test for overall effect: Z=2.56 (p=0.010)
Test for subgroup differences: ²=114.43, df=1 (p<0.001), I²=99.1% Favours placebo
Mean difference (95% CI)
Favours melatonin
Heterogeneity: τ²=0.00; ²=0.91, df=1 (p=0.340); I ²=0%
χ
χ
χ
–100 –50 0 50 100
Figure 1: Sleep diary-reported total sleep time: melatonin versus placebo and autism spectrum disorder (ASD) subgroup analysis. Squares represent
the point estimate of the individual study result. The squares also give a representation of the size of the study. Larger squares indicate more partici-
pants in the study. SE, standard error; CI, confidence interval; df, degrees of freedom. [Colour figure can be viewed at wileyonlinelibrary.com]
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did not receive a previous parent-directed sleep manage-
ment intervention (test for subgroup differences: p=0.48;
I2=0%). There was a single included trial where the study
population primarily had ASD;45 the overall mean differ-
ence reduced with removal of this study (pooled mean dif-
ference 22.9min, 95% CI 14.5–31.3, p<0.001). When mean
differences (adjusted for baseline values; Appleton: mean
difference 13.3 [SE 14.7]; Cortesi: 67.6 [10.4]; van der
Heijden: 33.4 [12.7]) were included in the meta-analysis
for the parallel-group RCTs, the overall pooled mean dif-
ference increased marginally to 32.3 minutes (95% CI
15.3–49.3, p<0.001).
One RCT without a washout period52 (n=12 analysed
participants) reported a mean difference in actigraphy-mea-
sured TST of 21 minutes between melatonin and placebo
favouring melatonin. The authors reported p-values of
0.0019 and 0.02 for this outcome on the basis of datasets
produced using two different approaches for dealing with
missing data (complete case and last observation carried
forward respectively). This outcome was also analysed by
the trial authors using a paired t-test, which produced a p-
value of 0.057. On the basis of this, we estimated the 95%
CI for the mean difference of 21 minutes as 0.7 to 42.7.
For TST based on polysomnography,51 which was not
pooled with the actigraphy-based measures, there was no
statistically significant difference (p=0.26) between mela-
tonin and placebo, with a reported mean difference of
39.3 minutes (favouring placebo, estimated 95% CI 34.7
to 113.3, n=10).
Sleep efficiency
Five RCTs (n=475 randomized participants) reported sleep
efficiency: that is, the ratio of TST to total time in bed. One
RCT used both actigraphy and parent-report,42 three used
actigraphy data only,18,45,46 and one trial used polysomnog-
raphy.51 One RCT additionally measured the percentage of
children who achieved sleep efficiency in the normative level
of more than 85% at the 12-week assessment.45
The four RCTs (n=254 analysed participants) reporting
actigraphy-measured sleep efficiency were pooled in a
meta-analysis. There was no statistically significant differ-
ence in sleep efficiency with melatonin compared with pla-
cebo (Fig. S3, online supporting information; pooled mean
difference 4.76% favouring melatonin, 95% CI 0.95 to
10.47, p=0.10). Heterogeneity was high (I2=94%) and this
treatment effect is unlikely to be generalizable. The trials
did consistently report very small differences between
groups in sleep efficiency, favouring melatonin, and these
differences are unlikely to be clinically meaningful. A sensi-
tivity analysis removing the results of Wasdell et al.42 was
performed because the means and SDs of the outcome for
this trial indicated that the data may have been non-nor-
mally distributed; the pooled mean difference increased
slightly to 6.32% (95% CI 0.14–12.51, p=0.05). When
mean differences adjusted for baseline (Appleton: mean dif-
ference 4.0 [SE 2.37]; Cortesi: 10.8 [1.15]; van der Heij-
den: 4.7 [1.81]) were included in the meta-analysis for the
parallel-group RCTs, the overall pooled mean difference
was 5.03% (95% CI 0.46 to 10.52, p=0.07).
There was no statistically significant difference in effect
between the studies where participants received or did not
receive a previous parent-directed sleep management inter-
vention (test for subgroup differences: p=0.34; I2=0%).
There was a single included trial where the study popula-
tion primarily had ASD;45 the overall mean difference
reduced with removal of this study (pooled mean difference
1.75%, 95% CI 0.43 to 3.92, p=0.12).
The single RCT reporting parent-reported sleep effi-
ciency (n=50 analysed participants) described no statisti-
cally significant difference between the groups (mean
difference 0.30% favouring melatonin, estimated 95% CI
0.90 to 1.49, p=0.62).42 However, the means and SDs
reported for each arm of the crossover trial in the original
paper indicated significant skew and there was no evidence
that data were transformed (e.g. log-transformed) to cor-
rect for this before analysis; thus the comparison of
Study and subgroup Mean difference SE Melatonin total
Placebo 
total Weight (%) Mean difference (95% CI)
Prior intervention
Appleton et al.18 29.3 20.4 30 29 11.2 29.30 (–10.68, 69.28)
Wasdell et al.42 23.4 7.9 50 50 23.1 23.40 (7.92, 38.88)
24.17 (9.73, 38.61)34.37980Subtotal
Heterogeneity: ²=0.00; χ²=0.07, df=1 (p=0.790); I ²=0% 
Test for overall effect: Z=3.28 (p=0.001)
No prior intervention
Cortesi et al.45 64.9 9.5 34 32 21.3 64.90 (46.28, 83.52)
der Heijden et al.46 18.5 11.5 41 39 19.1 18.50 (–4.04, 41.04)
Jain et al.51 23.2 5.9 10 10 25.2 23.20 (11.64, 34.76)
35.49 (7.70, 63.28)65.78185Subtotal
Heterogeneity: ²=519.89; ²=1 5.59, df=2 (p<0.001); I ²=87% 
Test for overall effect: Z=2.50 (p=0.010)
31.93 (14.76, 49.09)100.0160165Total
Heterogeneity: ²=269.16; ²=16.52, df=4 (p=0.002); I ²=76% 
Test for overall effect: Z=3.65 (p<0.001)
Test for subgroup differences: ²=0.50, df=1 (p=0.480), I ²=0% 
Favours placebo
Mean difference (95% CI)
Favours melatonin
–100 –50 0 50 100
τ
τ
τ
χ
χ
χ
Figure 2: Actigraphy-measured total sleep time: melatonin versus placebo. Squares represent the point estimate of the individual study result. The
squares also give a representation of the size of the study. Larger squares indicate more participants in the study. SE, standard error; CI, confidence
interval; df, degrees of freedom. [Colour figure can be viewed at wileyonlinelibrary.com]
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unadjusted means is likely to be inappropriate and there-
fore the results invalid.
One RCT45 reported the percentage of children who
achieved sleep efficiency in the normative range (>85%) as
46.4% of the melatonin group compared with 0% of the
placebo group.
Another RCT51 reported no statistically significant dif-
ference (p=0.17) in polysomnography-measured sleep effi-
ciency (mean difference 3.8% favouring melatonin,
estimated 95% CI 2.5 to 10.1, n=10). Again, assessment
of the means and SDs suggest data may have been skewed,
so the results should be treated with caution.
Sleep initiation
Ten RCTs (n=583 randomized participants) measured SOL,
defined as the time in minutes from the child being placed
in bed to sleep onset. Three RCTs reported parent-reported
SOL data only;47,48,50 two reported actigraphy-measured
SOL data only;45,52 four reported both actigraphy and par-
ent-reported SOL;18,42,43,46 and one reported outcomes
using polysomnography.51 One RCT additionally calculated
the percentage of children who either met a standard sleep
criterion for SOL of 30 minutes or less, or a reduction of
SOL by 50%.45 Another RCT used another measure of
SOL, defined as the duration of time between taking the
medication and falling asleep.48
For sleep diary SOL, six trials (n=223 analysed partici-
pants) were pooled, comprising five crossover trials with a
washout period (n=110)42,43,47,48,50 and one parallel-group
trial (n=113).18 There was a statistically significant decrease
(favouring melatonin) in SOL (Fig. S4, online supporting
information; pooled mean difference 35.6min, 95% CI
50.9 to 20.3, p<0.001). Heterogeneity was high
(I2=89%) and the treatment effect is unlikely to be general-
izable, although the individual effect estimates were all in
the direction of benefit with melatonin. When mean differ-
ences adjusted for baseline (Appleton: mean difference
37.5 [SE 9.1]) were included in the meta-analysis for the
parallel-group RCTs, the overall pooled mean difference
barely changed (35.6min, 95% CI 50.6 to 20.6,
p<0.001).
There was a statistically significant difference in effect
between the studies of children with ASD and those with
mixed and other populations (test for subgroup differences:
p<0.001; I2=93%). There was a larger difference in the
ASD group between melatonin and placebo with a mean
reduction in favour of melatonin of 50.9 minutes (95% CI
55.5 to 46.2) compared with 27.4 minutes (95% CI
39.1 to 15.7) in the other group (Fig. S4). A subgroup
analysis based on receipt of previous intervention could
not be conducted since all of the included trials offered
participants an additional intervention before the start of
the study.
Five RCTs (n=264 analysed participants) reporting acti-
graphy-measured SOL were pooled, comprising three paral-
lel-group trials (n=195)18,45,46 and two crossover trials with
a washout period (n=69).42,43 There was a statistically
significant decrease (favouring melatonin) in actigraphy-
reported SOL (Fig. S5, online supporting information;
pooled mean difference 23.4, 95% CI 30.9 to 15.8,
p<0.001). There was moderate heterogeneity (I2=48%).
When mean differences adjusted for baseline (Appleton:
mean difference –45.3 [SE 11.9]; Cortesi: 37.4 [7.6]; van
der Heijden: 24.3 [5.2]) were included in the meta-analysis
for the parallel-group RCTs, the overall pooled mean dif-
ference increased to 26.5 minutes (95% CI 35.3 to
17.8, p<0.001). For both sleep diary-reported and actigra-
phy-measured SOL, the single study with a low risk of
bias18 reported a statistically significant improvement (ad-
justed and unadjusted) with melatonin compared with pla-
cebo.
On the basis of the subgroup analysis there was no sta-
tistically significant difference between studies by whether
participants had or did not have a previous parent-directed
intervention (Fig. S5, online supporting information; test
for subgroup differences: p=0.55; I2=0%). There was a sin-
gle included trial where the study population primarily had
ASD;45 the overall mean difference reduced with removal
of this study (pooled mean difference 19.7min, 95% CI
25.5 to 13.9, p<0.001).
A statistically significant decrease in mean SOL was
reported for the crossover RCT without a washout period
(n=12 analysed participants). However, the mean difference
with the comparator group was not reported. When anal-
ysed using a paired t-test, the result was not statistically
significant (mean difference 28.08min, estimated 95% CI
2.5 to 58.7, p=0.10).52
For the RCTs that could not be pooled in the meta-ana-
lyses, one used an additional indicator of SOL (the per-
centage of children who met a criterion of SOL of 30min
or less, or a reduction of SOL by 50% after intervention),
and reported that 39% of the melatonin group versus 0%
of the placebo group achieved one of these changes (n=66
analysed participants).45 The RCT using polysomnography
(n=10) reported that melatonin significantly reduced the
mean SOL compared with placebo (mean difference
11.4min, estimated 95% CI 17.2 to 5.6, p=0.02).51
The RCT that measured the duration of time between
taking the medication and falling asleep (n=17) reported a
significant decrease in SOL with melatonin compared with
placebo (mean difference 51.7min, estimated 95% CI
16.5–86.9, p=0.01).48
Sleep maintenance
Six RCTs (n=142 randomized participants) reported the
number of night wakings.41,42,47,48,50,52 Four crossover
RCTs with a washout period were pooled (n=94 analysed
participants).42,47,48,50 There was no difference in the mean
number of night wakings with melatonin compared with
placebo (Fig. S6, online supporting information; pooled
mean difference 0.04, 95% CI 0.22 to 0.13, p=0.61).
Heterogeneity was high (I2=84%), although the results
consistently favoured melatonin with the exception of the
results of Dodge and Wilson.50 On the basis of the
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subgroup analysis, there was no statistically significant dif-
ference in effect between studies for type of neurodisability
(test for subgroup differences: p=0.06; I2=72%). A sub-
group analysis based on receipt of previous parent-directed
sleep management intervention could not be conducted
since all of the included trials offered participants such an
additional intervention before the start of the study. How-
ever, for all included trials, skew for this variable was
detected using the summary statistics so the validity of the
meta-analysis based on means is questionable and results
should be treated with caution.
The crossover study without a washout period reported
no significant difference for the melatonin period com-
pared with the placebo period either by the non-parametric
analyses or by the paired t-test (reported paired t-test mean
difference 0.07 favouring melatonin, p=0.73, estimated
95% CI 0.44 to 0.30).52 Another RCT reported no sta-
tistically significant difference (p=0.48) for melatonin com-
pared with placebo (mean difference 0.41 favouring
melatonin, 95% CI 1.47 to 0.66) for actigraphy-measured
number of waking episodes; however, these data are likely
to have a non-normal distribution so analyses based on
means, which were conducted by the original authors, may
not be appropriate.42
Other outcomes
Six of the 11 RCTs reported other outcomes.41,42,45,46,51,52
With the exception of waking after sleep onset (night wak-
ing duration and/or frequency after the child falls asleep),
which was reported by two studies,45,51 each outcome mea-
sure was only reported by a single study. These are sum-
marized in Table SIII (online supporting information).
Melatonin regimes
Two crossover RCTs involving a total of 24 randomized
participants each compared two different regimens of
melatonin. One,44 with no washout period, compared con-
trolled-release with fast-release melatonin; the other,49
with a 2-week washout period, compared a dose regimen
of 5mg with 10mg of melatonin (in this trial the formula-
tion of melatonin was not reported).49 The durations of
the interventions were 11 days and 2 weeks for Jan et al.44
and Hancock et al.49 respectively.
The mean ages of participants were 6 years 11 months49
and 9 years 4 months.44 Children in one RCT49 were
described as having a variety of severe neurodevelopmental
difficulties, whereas in the other44 all were diagnosed with
tuberous sclerosis complex. Sleep disturbance in both stud-
ies was sleep initiation and maintenance.
In one RCT44 the inclusion criterion was that children
had already been treated with fast-release melatonin for
more than 3 months, but slept for fewer than 5 to 6 hours
a night. No guidance on sleep management was provided
to parents before or during either of the RCTs.
The two RCTs measured four sleep-related outcomes:
one49 measured TST, SOL, and number of night wakings,
whereas the other44 measured ‘changes in sleep pattern’ as
the only outcome. The results of these outcomes are sum-
marized in Table SIV (online supporting information).
There was no evidence of benefit in terms of the formula-
tion of melatonin on any of the sleep-related outcomes in
the RCT comparing controlled-release and fast-release for-
mulations; the authors reported that possible reasons for the
lack of improvement in five children may have included
their inability to swallow the controlled-release tablets
whole (which was required to enable the coating to provide
the controlled-release effect). There was also no evidence of
differences in benefit for the RCT that compared a dose of
5mg of melatonin with 10mg of melatonin.
Adverse events
Adverse event data were reported in 11 of the 13
RCTs.18,42–46,48–52 However, these data was collected and
reported in different ways across the RCTs and no meta-
analysis was possible (Table SV, online supporting infor-
mation). Many adverse event data were collected, including
abdominal pain, agitation, anxiety, behaviour change/prob-
lems, breathlessness, cold/flu/infection, confusion, consti-
pation, diarrhoea, cough, daytime laziness, decreased
mood, dizziness, drowsiness, gastro intestinal illness,
impaired appetite, increased activity, increased excitability,
mood swings, seizures, rash, hypothermia, fatigue, head-
ache/migraine, ‘hung-over feeling’, tremor, nausea, vomit-
ing, nightmares, rash, mood swings, hypothermia,
irritation to skin hyperactivity, itching or painful lumps on
the skin, sleep maintenance insomnia, somnolence skin
pigment changes, perspiration, regression of development,
and visual disturbance.
Three trials reported that no adverse events were
observed or reported.44,45,52 The adverse event profile
seemed to be similar between the melatonin and placebo
groups, suggesting that melatonin was tolerated well.
DISCUSSION
Main findings
We set out to undertake a systematic review of existing lit-
erature to identify trials that evaluated the effectiveness of
pharmacological intervention(s) for managing sleep disturb-
ance in children with neurodisabilities. Thirteen eligible
RCTs were identified, all of which studied melatonin. The
quality of the evidence was poor, with only one RCT
assessed as having a low risk of bias. Just three child sleep
outcomes – variously measured using parent-report and
actigraphy – were reported by more than half of the stud-
ies, with many other sleep outcomes assessed by individual
studies. Eleven trials assessed the effectiveness of melatonin
compared with placebo, while two evaluated different regi-
mens of melatonin (controlled-release vs fast-release; and
5mg vs 10mg). We found evidence of benefit for melatonin
compared with placebo for TST and SOL; however, the
exact extent of the benefit, which children might benefit
the most, and the clinical significance of the benefit remain
uncertain. There was a lack of evidence around the clinical
significance of study findings, with only one trial assigning
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clinical significance.18 There was no statistically significant
evidence of benefit for sleep maintenance outcomes, such
as number of night wakings; however, some studies may
not have been sufficiently powered to detect an effect. In
addition, analyses of the comparison of means may not be
appropriate for such an outcome as it is likely to be non-
normally distributed; authors should take care to assess the
normality of their data and consider whether a log-trans-
formation (or other) is required to correct the skew before
data are summarized and analysed.39 The same applies to
sleep efficiency, which is expressed as a percentage. The
single trial comparing controlled-release and fast-release
melatonin found no difference in outcomes (although the
study authors noted that compliance was compromised in
the controlled-release arm). No evidence in difference of
benefit for any outcome was found in the single trial com-
paring 5mg and 10mg of melatonin. On the whole, the
studies identified did not assess parent or other child out-
comes. All included studies only evaluated follow-up out-
comes immediately after completion of the melatonin
treatment, meaning we were unable to determine its
longer-term effects.
Strengths and limitations
The review design and conduct were partly informed by a
public and patient involvement committee comprising pro-
fessionals and parents of children with neurodisabilities.
This has strengthened the findings reported here and
enabled the perspectives of parents during the design and
conduct of this review to be represented, and provided use-
ful contextual information for the review team.
We undertook thorough and systematic searches of 16
databases, without language restrictions, and included grey
literature. To minimize reviewer error and bias, two
researchers independently undertook key study processes
such as study selection and risk of bias assessment of studies.
Where possible, the synthesis grouped studies by type of
neurodisability, and whether the participants received a pre-
vious parent-directed sleep management intervention. How-
ever, subgroup analyses were restricted by the small number
of studies and the likelihood of confounding with other
study characteristics. The results of the subgroup analyses
should, therefore, be interpreted with caution. Additionally,
subgroup analyses are based on summary data and are there-
fore observational rather than randomized comparisons.
Owing to the nature of the outcomes measured, robust,
blinded outcome assessment is often unlikely to be feasible.
Although actigraphy-based child sleep outcomes are more
objective than parent-reported measures, we did not con-
sider these to be true objective outcomes, with non-blind-
ing unlikely to introduce bias.
Comparison with existing literature
In a recent national research prioritization exercise for chil-
dren with neurodisability, the management of sleep distur-
bance was ranked in the top ten research priorities.8 Our
review was undertaken as part of a larger systematic review
funded by the Health Technology Assessment programme
of the UK National Institute for Health Research,31 which
assessed the effectiveness of pharmacological and non-phar-
macological interventions for non-respiratory sleep distur-
bance in children with neurodisabilities. We did not identify
any trials of pharmacological interventions other than mela-
tonin that met our inclusion criteria.
This review includes children with neurodisabilities, with
some having comorbidities (e.g. epilepsy). This is a hetero-
geneous population; and coupled with the small numbers
of studies identified, this hindered our ability to accurately
estimate the relative impact of melatonin for specific
groups of children. This is similar to the conclusion
reached by Appleton et al.18
Implications of findings for clinical practice and research
Owing to uncertainty in the evidence, it is not appropriate
to make definitive conclusions about the role of melatonin in
the treatment of non-respiratory sleep disturbances in chil-
dren with neurodisabilities. The meta-analyses found sub-
stantial heterogeneity when all the studies were pooled, but
subgroup analysis based on whether the population had a
diagnosis of ASD or not suggested that the treatment effect,
at least with respect to some sleep outcomes, may vary across
diagnostic groups with the effect greatest in children with
ASD. This might reflect differences in the aetiology of the
sleep disturbance in children with ASD compared with chil-
dren with other neurodisabilities, with relatively low levels
of melatonin reported in children with ASD.53–55
Our findings also indicate that melatonin is one option
for the management of sleep initiation in this population.
However, given that there was no greater benefit of mela-
tonin in children whose parents had not previously
received a parent-directed sleep management intervention,
our findings support existing recommendations that mela-
tonin should only be used where sleep problems persist
after such an intervention has been implemented.20,24
Future research directly comparing the two interventions,
or evaluating their parallel use, with respect to the man-
agement of sleep initiation would be useful.
Studies included in this review used a wide variety of dif-
ferent outcomes and measurement tools. This limited our
ability to undertake effective syntheses of the studies. For
example, the only outcome measured by most studies and
assessed in similar ways was TST. There was also variabil-
ity in the outcome domains of interest: for instance, sleep
maintenance outcomes were assessed in some studies but
not others. Poor reporting by many studies of the specific
nature of the children’s sleep disturbance meant it was not
possible to judge whether this variability in choice of out-
come domains was due to differences in sleep disturbance.
Furthermore, there was variability in the measure used to
assess specific outcome domains. For adverse events there
was also variability in the type of adverse event reported,
data collection methods used, and reporting.
Thus there is a need for standardization of measures used
in future trials, and in terms used to define sleep problems. A
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core outcome set would enable comparison between studies
and ensure outcomes that are assessed are of relevance to key
stakeholders. Future work with families to identify minimally
important differences in these outcome measures is also
essential. There is also a need to identify other relevant child
and parent outcomes as well as the time-points at which out-
comes should be measured. In particular, the effect of mela-
tonin on longer-term outcomes, after the cessation of the
medication, needs to be assessed. Furthermore, to improve
clinical relevance, future studies of melatonin should specifi-
cally consider breaking down their included populations
according to children’s ages, and whether they were recruited
from community or clinical cohorts. No other types of phar-
macological intervention were identified that met the inclu-
sion criteria for this review. Thus there is a need to evaluate
alternative pharmacological treatments that have a different
mechanism of action to melatonin as the evidence suggests
uncertainty about the magnitude of any benefit of melatonin,
and that some populations may benefit less than others. It
would also be helpful to compare the effectiveness of mela-
tonin with alternative pharmacological interventions that act
on neurophysiological sleep mechanisms, such as sedation.
None of the studies on clonidine – a sedative known to be
used with children56 – met our eligibility criteria; therefore
further research is needed to clarify any possible role clonidine
may have. Further research is also needed on different formu-
lations and dosages of pharmacological interventions.
CONCLUSIONS
There is some evidence of benefit for melatonin compared
with placebo on the management of sleep disturbances in
children with neurodisabilities, but the degree and duration
of benefit, which children might benefit most, and the sig-
nificance of the benefit to the well-being of the child/fam-
ily remain uncertain because of the diverse populations in
the studies and the predominantly poor-quality evidence.
The adverse event profile suggested that melatonin was
well-tolerated. Subgroup analysis suggested that benefit
may be greatest for populations with ASD; however, this
should be interpreted with caution and further research is
required before definitive recommendations can be made.
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Table SV: Adverse events in studies evaluating melatonin
Appendix S1: Search strategy in Medline.
Figure S1: Flow chart of the study selection process.
Figure S2: Sleep diary-reported total sleep time: melatonin
versus placebo and prior intervention subgroup analysis.
Figure S3: Actigraphy-measured sleep efficiency: melatonin
versus placebo.
Figure S4: Sleep diary-reported sleep onset latency: melatonin
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Figure S6: Parent-reported number of night wakings: mela-
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